The Sylmar, Calif.-based company said that its Argus II systems have been used in their first commercial procedure in the region, implanted last month in a 62-year-old patient with retinal degeneration at the Singapore National Eye Center by Dr. Edmund Wong and Dr. Laurence Lim with supervision from Dr. Emin Özmert.
The Argus II induces visual perception in blind patients with retinitis pigmentosa by stimulating of the retina’s remaining cells with electrical pulses, which allows for the perception of light patterns to the brain, Second Sight Medical said.
“We are delighted to have completed our first Argus II surgery in Singapore, in collaboration with another leading international eye center. This further increases the global reach of the Argus II to individuals with Retinitis Pigmentosa (RP). The growing adoption of Argus II continues to validate its benefit to patients by offering them some functional vision. We look forward to ongoing growth in Singapore and other markets,” prez & CEO Will McGuire said in a press release.
Earlier this month, Second Sight announced the first trial implantation of its Orion cortical visual prosthesis system and updated on implantations of its Argus device and enrollment in an upcoming study.